This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kartsonis, N.
Right arrow Articles by Motyl, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kartsonis, N.
Right arrow Articles by Motyl, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3616-3623, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3616-3623.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

Nicholas Kartsonis,* John Killar, Lori Mixson, Chao-Min Hoe, Carole Sable, Kenneth Bartizal, and Mary Motyl

Merck Research Laboratories, West Point, Pennsylvania

Received 12 April 2005/ Returned for modification 16 May 2005/ Accepted 28 June 2005

The caspofungin clinical trial database offers an opportunity to assess susceptibility results for Candida pathogens obtained from patients with candidiasis and allows for correlations between efficacy outcomes and MICs. Candida isolates have been identified from patients enrolled in four studies of esophageal candidiasis and two studies of invasive candidiasis. The MICs of caspofungin for all baseline isolates were measured at a central laboratory using NCCLS criteria (document M-27A); MICs for caspofungin were defined as the lowest concentration inhibiting prominent growth at 24 h. MICs were then compared to clinical and microbiological outcomes across the two diseases. Susceptibility testing for caspofungin was performed on 515 unique baseline isolates of Candida spp. obtained from patients with esophageal candidiasis. MICs for caspofungin ranged from 0.008 to 4 µg/ml; the MIC50 and MIC90 were 0.5 and 1.0 µg/ml, respectively. Susceptibility testing was also performed on 231 unique baseline isolates of Candida spp. from patients with invasive candidiasis. The majority (~96%) of MICs were between 0.125 and 2 µg/ml, with MIC50 and MIC90 for caspofungin being 0.5 and 2.0 µg/ml, respectively. Overall, caspofungin demonstrated potent in vitro activity against clinical isolates of Candida species. A relationship between MIC for caspofungin and treatment outcome was not seen for patients with either esophageal candidiasis or invasive candidiasis. Patients with isolates for which the MICs were highest (>2 µg/ml) had better outcomes than patients with isolates for which the MICs were lower (<1 µg/ml). Additionally, no correlation between MIC and outcome was identified for specific Candida species.

* Corresponding author. Mailing address: Merck Research Laboratories, Merck & Co., Inc., BL 3-4, P.O. Box 4, West Point, PA 19486-0004. Phone: (484) 344-7301. Fax: (484) 344-3370. E-mail: nicholas_kartsonis{at}merck.com.

Antimicrobial Agents and Chemotherapy, September 2005, p. 3616-3623, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3616-3623.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Garcia-Effron, G., Kontoyiannis, D. P., Lewis, R. E., Perlin, D. S. (2008). Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies. Antimicrob. Agents Chemother. 52: 4181-4183 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E. (2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
  • Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., Ramani, R. (2008). Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. J. Clin. Microbiol. 46: 2155-2159 [Abstract] [Full Text]  
  • Kabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., Ribaud, P. (2008). Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. haematol 93: 639-640 [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150-156 [Abstract] [Full Text]  
  • Johnson, E. M. (2008). Issues in antifungal susceptibility testing. J Antimicrob Chemother 61: i13-i18 [Abstract] [Full Text]  
  • Milici, M. E., Maida, C. M., Spreghini, E., Ravazzolo, B., Oliveri, S., Scalise, G., Barchiesi, F. (2007). Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin. J. Clin. Microbiol. 45: 3529-3533 [Abstract] [Full Text]  
  • Collins, C. D., Eschenauer, G. A., Salo, S. L., Newton, D. W. (2007). To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias. J. Clin. Microbiol. 45: 1884-1888 [Abstract] [Full Text]  
  • Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., Graybill, J. R. (2007). In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera. Antimicrob. Agents Chemother. 51: 1616-1620 [Abstract] [Full Text]  
  • Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., Louie, A. (2007). Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. Antimicrob. Agents Chemother. 51: 968-974 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1.. Am J Health Syst Pharm 63: 1693-1703 [Abstract] [Full Text]  
  • Bennett, J. E. (2006). Echinocandins for Candidemia in Adults without Neutropenia. NEJM 355: 1154-1159 [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., Scalise, G. (2006). Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis.. Antimicrob. Agents Chemother. 50: 2719-2727 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»